Russell Frank Company’s KalVista Pharmaceuticals KALV Stock Holding History

Russell Frank Company’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-50	Closed	-$3K	–	3002
2015 Q4	$3K	Sell	50 -2,022	-98%	-$106K	﹤0.01%	2974
2015 Q3	$103K	Buy	2,072 +2,022	+4,044%	+$172K	﹤0.01%	2821
2015 Q2	$5K	Buy	+50	New	+$4.96K	﹤0.01%	3031

Other funds holding KALV

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Frank Company's KALV Position: Q1 2016 in Review

Russell Frank Company sold out of KalVista Pharmaceuticals (KALV) in Q1 2016, closing a stake of 50 shares — an estimated $3K sold.

Russell Frank Company first reported a position in KALV in Q2 2015 and held it in 3 quarters. The position peaked at $103K in Q3 2015. 32 funds tracked by Wall St. Rank hold KALV as of Q1 2016.

Russell Frank Company reported no remaining KalVista Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Russell Frank Company sold 50 KalVista Pharmaceuticals shares in Q1 2016, an estimated $3K.
Russell Frank Company first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Russell Frank Company's KalVista Pharmaceuticals position peaked at $103K in Q3 2015.
32 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.